

Ref: SEC/SE/2022-23 Date: August 04, 2022

To, Corporate Relation Department BSE Ltd Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001

BSE Scrip Code: 500096

National Stock Exchange of India Ltd Exchange Plaza, 5th Floor Plot No. C/1, G Block Bandra – Kurla Complex Bandra (E), Mumbai – 400051

NSE Scrip Symbol: DABUR

Sub: Investor Communication

Dear Sir,

In compliance of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to enclose a copy of Investor Communication being issued by the company today for your records.

This is for your information and records.

Thanking You,

Yours faithfully,

For Dabur India Limited

(A K Jain) E V P (Finance) and Company Secretary

Encl: as above



Results Presentation

4 August 2022




AGENDA



Q1 FY23: Performance Summary



Q1 FY23: Business Highlights




AGENDA




Q1 FY23: Performance Summary




Q1 FY23: Business Highlights



Q1 FY23 - Consolidated Financials




Domestic FMCG Growth - By Verticals




Note: Revenue of the verticals are in INR cr

International Business Performance



International Business grew by 8% in CC terms (flat in INR terms)






AGENDA



Q1 FY23: Performance Summary



Q1 FY23: Business Highlights



Q1 FY23 | Business Highlights - Healthcare

	Health Supplements	Digestives	OTC & Ethicals
Growth %	(35.5%)	30.5%	(15.4%)
3-year CAGR	9.0%	9.6%	13.9%
	 Health Supplements declined on account of high bases of Chyawanprash and Honey in Q1 FY22 and Q1 FY21 Dabur Glucose registered strong 	 The portfolio saw strong growth on account of robust double- digit growth in both Hajmola and Pudin Hara 	 Declined on account of high bases of Covid contextual products in Q1 FY22 and Q1 FY21
Category Highlights	 double-digit growth on the back of robust execution and intense summer season. Market share in Chyawanprash category increased by ~240 bps Market share in Honey category increased by ~190 bps Dabur Vedic Green Tea Detox Kahwa launched in Q1 FY23 	 Hajmola Amla Candy launched in chatpata flavour in the tasty digestives space 	 Following new products launched during the quarter 1. Dabur Castor Oil 100% Cold Pressed 2. Dabur Shuddh Shilajit 3. Dabur Shodhit Guggulu 4. Dabur Aampachak Kadha 5. Dabur Gulkand

Dabur

A blend of 8 real Ayurvedic Herbs, Green Tea and Rock Salt



DETOX KAHWA






Resealable Zip Lock Pack

Soosts Immunity Rich Source of Vitamin C

Tear Here to open

Tasty Digestive with the Goodness of Amla

Tasty Digestive with the Goodness of Amla











HEALTH & WELLBEING REVITALIZER



Shuddh Shilajit

USEFUL IN







Don't let Painful Joints Restrict your Mobility



SHODHIT GUGGULU

FOR JOINT PAINS







GULKA

NO ARTIFICIAL

100%

AYURVED

प्रवाल यत्त

FLAVOURS

100% AYURVED

100% Natural, Delicious & Healthy Gulkand

Specialities of Dabur Gulkand



PREMIUM INGREDIENTS Rose Petals, Mishri and Praval Pishti



NATURAL TASTE & HEALTHY

Dabur Gulkand is manufactured without any artificial flavourings.



IMPORTANCE OF SUN PROCESSING

Ensures complete assimilation of all the ingredients

Q1 FY23 | Business Highlights - Home & Personal Care

	Hair Oils	Shampoo	Oral Care	Home Care	Skin & Salon
Growth %	8.1%	17.0%	12.5%	51.9%	11.4%
3-year CAGR	3.6%	14.4%	11.3%	11.3%	Flat
Category Highlights	 Hair oils portfolio recorded 8.1% growth on a high base of 38.4% Market share for hair oils portfolio improved by ~30 bps Vatika Neelibhringa21 Oil launched to enter the premium ayurvedic therapeutic oils market 	 Shampoos portfolio continued on strong growth trajectory, growing at 17% despite a high base of 41.3% growth Market share in shampoo category increased by ~50 bps 	 Toothpaste portfolio recorded 13.7% growth driven by good growth in Dabur Red, Meswak and Dabur Herb'l Market share in toothpaste category improved by ~20 bps 	 Robust double-digit growth for Odonil, Odomos and Sanifresh Odonil saw its MS improve in all subsegments of the air fresheners category Odomos' MS increased by ~190 bps Odonil Neem launched during the quarter 	 Ex-Sanitize, Skin care portfolio registered 35% growth Key brands Fem, Oxy and Gulabai registered strong growth





Odonil TRANSFORM YOUR WORLD

Q1 FY23 | Business Highlights - Food & Beverage (F&B)

	Beverages	Foods
Growth %	50.7%	35.7%
3-year CAGR	20.2%	15.7%
Category Highlights	 Beverage business continued to exhibit strong momentum across segments In-home and out-of-home portfolios registered strong growths Market share of Real Fruit Juice increased by ~330 bps Drinks and milkshakes added to the total addressable market expansion and are seeing good traction New launches during the quarter: Real Vitamin Boost Range, Real Chocolate Frappe and Real Café Frappe, Dabur Kesaria Thandai, Dabur Badam Kesaria 	 Hommade brand continued to perform well driven by innovation and portfolio expansion





Milleshales SLURPINGLY DELICIOUS NEW FRAPPE

Milk Powe

BOURBON CHOCOLATE

Chocolate Frappé Bourbon Chocolate

Milk Pov Cafe

Coffee

MOROCCAN COFFEE



Summarised Financial Statements



Consolidated P&L

	Q1 FY23	Q1 FY22	Y-o-Y (%)
Revenue from operations	2,822.4	2,611.5	8.1%
Other Income	100.5	84.8	18.5%
Total Income	2,923.0	2,696.4	8.4%
	617.0	628.7	(1.9%)
Material Cost	1,528.1	1,355.3	12.7%
% of Revenue	54.1%	51.9%	
Employee expense	269.9	258.2	4.5%
% of Revenue	9.6%	9.9%	
Advertisement and publicity	157.2	188.4	(16.5%)
% of Revenue	5.6%	7.2%	
Other Expenses	323.6	257.6	25.6%
% of Revenue	11.5%	9.9%	
Operating Profit	543.6	552.0	(1.5%)
% of Revenue	<i>19.3%</i>	21.1%	
EBITDA	644.2	636.9	1.1%
% of Revenue	22.8%	24.4%	
Finance Costs	12.1	7.5	61.9%
Depreciation & Amortization	67.6	61.3	10.3%
Profit before exceptional items, tax and share of profit/(loss) from joint venture	564.4	568.1	(0.6%)
% of Revenue	20.0%	21.8%	
Share of profit / (loss) of joint venture	(0.3)	(0.1)	409.2%
Exceptional item(s)	0.0	0.0	n.m.
Tax Expenses	123.1	129.7	(5.1%)
Net profit after tax and after share of profit/(loss) from joint venture	441.1	438.3	0.6%
% of Revenue	15.6%	16.8%	
Non controlling interest	0.7	1.0	(23.7%)
Net profit for the period/year	440.3	437.3	0.7%
% of Revenue	<i>15.6%</i>	<i>16.7%</i>	

Standalone P&L

	Q1 FY23	Q1 FY22	Y-o-Y (%)
Revenue from operations	2,179.7	1,982.8	9.9%
Other Income	84.2	71.2	18.3%
Total Income	2,263.9	2,054.0	10.2%
Naterial Cost	1,228.4	1,061.9	15.7%
% of Revenue	56.4%	53.6%	
Employee expense	172.6	161.5	6.9%
% of Revenue	7.9%	8.1%	
Advertisement and publicity	130.3	150.6	(13.4%)
% of Revenue	6.0%	7.6%	
Other Expenses	220.7	171.5	28.6%
% of Revenue	10.1%	8.7%	
Operating Profit	427.7	437.3	(2.2%)
% of Revenue	<i>19.6%</i>	<i>22.1%</i>	
EBITDA	511.9	508.5	0.7%
% of Revenue	<i>23.5%</i>	25.6%	
Finance Costs	7.0	2.3	207.4%
Depreciation & Amortization	44.0	38.6	13.9%
Profit before exceptional items, tax and share of profit/(loss) from joint venture	460.9	467.6	(1.4%)
% of Revenue	21.1%	23.6%	
Exceptional item(s)	0.0	0.0	n.m.
Tax Expenses	110.9	115.2	(3.8%)
Net profit for the period/year	350.1	352.4	(0.7%)
% of Revenue	<i>16.1%</i>	17.8%	

• • 25

For more information and updates, visit: http://www.dab ur.com/in/enus/investor

